PROVEN EFFICIENCY ON ANIMALS
Through the personal investments of the research associates supported by external investors, about ten animal studies have validated the effect of the positive technology on patient survival prolongation, its safety and reproducibility of the manufacturing process.
APAVAC, AN AUTOLOGOUS THERAPEUTIC VACCINE BASED ON AN UNPRECEDENTED APPROACH
This innovative and patented method is manufactured in France by Urodelia. It comes in the form of kits sold under the name of apa.vac® to veterinary oncologists. The kit is already distributed in 8 countries across Europe.
- Preparation and simple process (2h)
- Animal welfare without general side effects
- Compatibility with everyday life
- Affordable price
Today, more than 400 animals (dogs, cats, horses), covering 15 distinct pathologies, have been treated by apa.vac® since 2009.
The patient’s immune system with cancer does not recognize abnormal proteins produced by its own pathology. In the case of lymphoma, thanks to apa.vac®, the veterinary oncologist removes a neoplasic lymph node and separates abnormal proteins.
It then purifies these same proteins and re-injects them in the animal’s body, so that it becomes by itself capable of reacting to these proteins made visible to the organization through hydroxyapatite.
The immune system is then «re-educated». It becomes vigilant again and produces a response against its own cancer.